A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 09 Dec 2017
At a glance
- Drugs Seviteronel (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms CLARITY; CLARITY-1
- Sponsors Innocrin Pharmaceuticals
- 09 Dec 2017 Initial results (data cut off: 1 June, 2017; n=7) from phase II part of the study, presented at the 40th Annual San Antonio Breast Cancer Symposium.
- 16 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2018.
- 16 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History